This article is more than 5 years old. Information may no longer be current.

Abyrx receives FDA clearance for absorbable hemostatic bone putty

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has cleared Abyrx’s new Absorbable Hemostatic Bone Putty for clinical use in the United Stated, expanding the company’s surgical hemostat product offerings.

The ready-to-use Absorbable Hemostatic Bone Putty (AHBP) does not require mixing or stirring and achieves hemostasis by mechanical tamponade. According to a company press release, the putty consists of water-soluble and dissolvable components that completely absorb within days after surgery. Abryx offers AHBP in several sizes.

“AHBP and other products under development complement our Hemasorb products and will provide surgeons with more options to treat their patients and help enable hospitals to reduce costs,” John J. Pacifico, president and chief executive officer of Abryx, stated in the release.